The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial

Peter C.t. Hawkins, Adam J. Schwarz, James Stone, Fiona Pepper, James Gilleen, Sam Gijsen, Ndaba Mazibuko, Dimitrios Arkilo, Wei Yin, Jingtao Wu, Polyna Khudyakov, Rhett Behrje, Laura Rosen, Joel A. Posener, Mitul A. Mehta, Antonio LaurenzaPsychopharmacology 2025 · DOI

Abstract

The negative and cognitive symptoms of schizophrenia are predictive of quality of life and functional recovery, but there are no approved drug options that target these symptoms directly. TAK-041 (also known as NBI-1065846) is a selective and potent small-molecule agonist of GPR139, an orphan G-protein-coupled receptor, which has been shown to reverse deficits related to negative and cognitive symptoms in animal models. In this proof-of-activity study to evaluate the effects of TAK-041 on motivational anhedonia, 23 adults with schizophrenia experiencing moderate to severe negative symptoms were administered a single 40 mg or 160 mg dose of TAK-041 in a randomised, double-blind, placebo-controlled, two-period crossover design. Functional magnetic resonance imaging (fMRI) assessment of reward function (monetary incentive delay [MID] task) and cerebral blood flow (CBF), as well as cognitive assessment with the Brief Assessment of Cognition in Schizophrenia (BACS) tool, were performed 3 h post dose and after 14 days. There was no significant effect of TAK-041 compared with placebo on BACS score at either timepoint. There was also no significant effect of TAK-041 on MID fMRI at day 1; however, at day 14, TAK-041 produced an increase in reward anticipatory activity in the ventral striatum compared with placebo. There was a significant decrease in CBF throughout the brain at day 1 that then reversed, resulting in a relative increase at day 14, compared with placebo. At day 14 there was a significant interaction between drug and CBF on reward anticipatory BOLD, indicating that drug-related changes to CBF may partially contribute to the observed BOLD effects (although the main effect of drug on the BOLD signal remained significant after including CBF as a covariate in the model). These data indicate that TAK-041 produces detectable changes in both CBF and reward task related fMRI signal in brain regions linked with symptoms and treatment response in schizophrenia.

Introduction

Current pharmacological treatments for schizophrenia primarily target "positive" symptoms, such as hallucinations and delusions, by modulating dopamine D2 receptors. However, the "negative" symptoms—including anhedonia (inability to feel pleasure) and avolition (lack of motivation)—along with cognitive deficits, remain largely unaddressed and are the strongest predictors of long-term functional impairment.

This study investigates TAK-041, a selective agonist of the orphan G-protein-coupled receptor GPR139. Preclinical evidence suggests that GPR139 activation can reverse social and cognitive deficits. This trial aimed to translate those findings to humans, specifically examining whether TAK-041 could normalize dysfunctional reward processing in the brain's striatum, a region often underactive in patients with schizophrenia.

Study Design and Methodology

The researchers employed a randomised, double-blind, placebo-controlled, two-period crossover design involving 23 adults with schizophrenia. Participants were assigned to receive either a single dose of TAK-041 (40 mg or 160 mg) or a placebo in the first period, followed by a washout period of 35 to 42 days before crossing over to the alternate treatment.

Study design of the randomised, double-blind, placebo-controlled crossover trial.

Neuroimaging and cognitive assessments were conducted at two critical timepoints: 3 hours post-dose (Day 1) and 14 days post-dose (Day 14). The primary assessments included:

  1. Arterial Spin Labelling (ASL): To measure resting Cerebral Blood Flow (CBF).
  2. Monetary Incentive Delay (MID) Task: A task-based fMRI paradigm used to measure Blood Oxygen Level Dependent (BOLD) activity during reward anticipation.
  3. Brief Assessment of Cognition in Schizophrenia (BACS): A standardized tool to evaluate cognitive performance.
The Monetary Incentive Delay (MID) task structure used to assess reward anticipation.

Key Insights and Results

The Temporal Shift in Reward Processing

The most significant finding was the time-dependent nature of the drug's effect. On Day 1, no significant differences were observed in reward-related brain activity between the TAK-041 and placebo groups. However, by Day 14, the 160 mg dose of TAK-041 produced a significant increase in reward anticipatory activity in the ventral striatum (posterior probability > 0.83). This suggests that the drug does not act as an immediate switch but rather facilitates a gradual modulation of neural reward circuits, likely due to its exceptionally long half-life of approximately 300 hours.

Hemodynamic vs. Neural Effects

A critical challenge in neuropharmacology is distinguishing between changes in neural activity and changes in global blood flow. On Day 1, TAK-041 caused a widespread decrease in CBF. By Day 14, this effect reversed, showing a relative increase compared to placebo. By using the CBF data as a covariate in the fMRI analysis, the researchers confirmed that while hemodynamic changes contributed to the signal, TAK-041 exerted a genuine, independent effect on the reward system's functional response.

Cognitive and Safety Outcomes

Despite the changes in reward-related brain activity, there was no significant effect on BACS cognitive scores at either Day 1 or Day 14. This may indicate that cognitive improvements require longer-term dosing or that GPR139 modulation does not directly impact the specific cognitive domains measured by the BACS. The drug was generally well-tolerated, with plasma exposure increasing in a dose-dependent manner.

Limitations and Future Directions

As a proof-of-activity trial, the study is limited by its small sample size (n=23). Furthermore, the long half-life of TAK-041 posed challenges for the crossover design, as some participants had residual drug levels during their placebo phase.

Future research should explore chronic, multi-dose regimens to determine if the observed "pro-motivational" brain changes at Day 14 translate into sustained clinical improvements in negative symptoms and real-world functional recovery for patients with schizophrenia.

Summary updated

Abstract

The negative and cognitive symptoms of schizophrenia are predictive of quality of life and functional recovery, but there are no approved drug options that target these symptoms directly. TAK-041 (also known as NBI-1065846) is a selective and potent small-molecule agonist of GPR139, an orphan G-protein-coupled receptor, which has been shown to reverse deficits related to negative and cognitive symptoms in animal models. In this proof-of-activity study to evaluate the effects of TAK-041 on motivational anhedonia, 23 adults with schizophrenia experiencing moderate to severe negative symptoms were administered a single 40 mg or 160 mg dose of TAK-041 in a randomised, double-blind, placebo-controlled, two-period crossover design. Functional magnetic resonance imaging (fMRI) assessment of reward function (monetary incentive delay [MID] task) and cerebral blood flow (CBF), as well as cognitive assessment with the Brief Assessment of Cognition in Schizophrenia (BACS) tool, were performed 3 h post dose and after 14 days. There was no significant effect of TAK-041 compared with placebo on BACS score at either timepoint. There was also no significant effect of TAK-041 on MID fMRI at day 1; however, at day 14, TAK-041 produced an increase in reward anticipatory activity in the ventral striatum compared with placebo. There was a significant decrease in CBF throughout the brain at day 1 that then reversed, resulting in a relative increase at day 14, compared with placebo. At day 14 there was a significant interaction between drug and CBF on reward anticipatory BOLD, indicating that drug-related changes to CBF may partially contribute to the observed BOLD effects (although the main effect of drug on the BOLD signal remained significant after including CBF as a covariate in the model). These data indicate that TAK-041 produces detectable changes in both CBF and reward task related fMRI signal in brain regions linked with symptoms and treatment response in schizophrenia. IND Number: 130074| EudraCT Number: 2017-001084-20| Clincaltrails.gov registry: NCT03319953.
BibTeX
@inproceedings{hawkins2025gpr,
  author = {Peter C.T. Hawkins and Adam J. Schwarz and James Stone and Fiona Pepper and James Gilleen and Sam Gijsen and Ndaba Mazibuko and Dimitrios Arkilo and Wei Yin and Jingtao Wu and Polyna Khudyakov and Rhett Behrje and Laura Rosen and Joel A. Posener and Mitul A. Mehta and Antonio Laurenza},
  title = {{The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial}},
  booktitle = {Psychopharmacology},
  year = {2025},
  doi = {10.1007/s00213-025-06884-x},
}
Figure